GGrantIndex
← Leaderboards

Krishanu Saha

University Of Wisconsin-Madison

Google Scholar ↗PubMed ↗ORCID ↗
$8,638,524
Attributed
$15,939,126
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.5M · FY2016–25
$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$33,016,858 · 11

By mechanism

U19$19,402,637 · 4
R35$3,976,712 · 1
U01$3,055,117 · 3
UH3$2,404,322 · 1
UG3$2,253,202 · 1
R01$1,924,868 · 1

Top collaborators

Most similar at University Of Wisconsin-Madison

Same institution · by research overlap

Others in their field

Top investigators on “Cells”

Research focus

CellsGenesGenome EditingCrispr/Cas TechnologyInnovationProgramsClustered Regularly Interspaced Short Palindromic RepeatsGenomeTissuesIn VitroMutationProductionInduced Pluripotent Stem CellVisionMonitorRetinaTechnologyLeadImageCustomFutureFoundationsUnited States National Institutes Of HealthImmune Response

Grant awards (36)

The CRISPR Vision Program: Nonviral Genome Editing Platforms to Treat Inherited Retinal Channelopathies$4,343,177
U19 · FY2025 · NS · contact PI
Label-free imaging of CAR T cell metabolism$647,057
R01 · FY2025 · CA
Streamlined development of an IND with the silica nanocapsule loaded with Cas9 genome editors to disrupt the dominant BEST1 mutant allele$461,538
U19 · FY2025 · NS · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$415,684
R35 · FY2025 · GM · contact PI
Administrative Core$110,044
U19 · FY2025 · NS · contact PI
Replication Study of Off-Target Assays for Guide RNAs in CRISPR-Based Therapeutics$77,750
U19 · FY2025 · NS · contact PI
The CRISPR Vision Program: Nonviral Genome Editing Platforms to Treat Inherited Retinal Channelopathies$6,363,061
U19 · FY2024 · NS · contact PI
Streamlined development of an IND with the silica nanocapsule loaded with Cas9 genome editors to disrupt the dominant BEST1 mutant allele$693,945
U19 · FY2024 · NS · contact PI
Label-free imaging of CAR T cell metabolism$615,789
R01 · FY2024 · CA
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$415,684
R35 · FY2024 · GM · contact PI
Health equity in the development of somatic cell genome editors for retinal disease$134,598
U19 · FY2024 · NS · contact PI
Health equity in the development of somatic cell genome editors for retinal disease$134,598
U19 · FY2024 · NS · contact PI
Administrative Core$110,046
U19 · FY2024 · NS · contact PI
The CRISPR Vision Program: Nonviral Genome Editing Platforms to Treat Inherited Retinal Channelopathies$6,159,146
U19 · FY2023 · NS · contact PI
Streamlined development of an IND with the silica nanocapsule loaded with Cas9 genome editors to disrupt the dominant BEST1 mutant allele$696,915
U19 · FY2023 · NS · contact PI
Label-free imaging of CAR T cell metabolism$662,022
R01 · FY2023 · CA
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$415,684
R35 · FY2023 · GM · contact PI
Administrative Core$117,819
U19 · FY2023 · NS · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$1,212,189
UH3 · FY2022 · NS
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$611,987
U01 · FY2022 · EY · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$415,684
R35 · FY2022 · GM · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$1,192,133
UH3 · FY2021 · NS
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$611,987
U01 · FY2021 · EY · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$415,578
R35 · FY2021 · GM · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$750,461
UG3 · FY2020 · NS
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$611,987
U01 · FY2020 · EY · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$369,780
R35 · FY2020 · GM · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$750,461
UG3 · FY2019 · NS
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$602,712
U01 · FY2019 · EB · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$369,780
R35 · FY2019 · GM · contact PI
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain$752,280
UG3 · FY2018 · NS
Single Cell Profiling To Define Biomarkers Of Photoreceptor Dysfunction After Gene Editing Within PSC-Derived Organoids$616,444
U01 · FY2018 · HL · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$369,780
R35 · FY2018 · GM · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$49,500
R35 · FY2018 · GM · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$369,780
R35 · FY2017 · GM · contact PI
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells$369,778
R35 · FY2016 · GM · contact PI